Award Number:  DAMD17-03-1-0429

TITLE:  Proteomic Analysis to Identify Novel Circulating Breast Cancer Markers

PRINCIPAL INVESTIGATOR:  Francisco J. Esteva, M.D., Ph.D.

CONTRACTING ORGANIZATION:  University of Texas M.D. Anderson Cancer Center
Houston, Texas  77030

REPORT DATE:  June 2004

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT:  Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.
Proteomic Analysis to Identify Novel Circulating Breast Cancer Markers

Francisco J. Esteva, M.D., Ph.D.

The University of Texas M.D. Anderson Cancer Center
Houston, Texas 77030

E-Mail: festeva@mdanderson.org

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

The purpose of our proposed work is to study differences in serum protein expression profiles between healthy women and women with breast cancer, and to discover novel tumor markers. We intend to generate proteomics spectra on serum samples from 100 healthy women and 100 breast cancer patients. The goal of this analysis is to identify serum proteomic patterns using a matrix-assisted laser desorption ionisation that can distinguish women with breast cancer from healthy women. The origin and full identity of the discriminating proteins or peptides will be investigated.

The protocol is under review by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I received their first review of the protocol and informed consent on January 21, 2004, and replied to their comments and concerns on January 30, 2004. I received a second review with additional comments on June 1, 2004 and I replied on June 10, 2004. I am still waiting for the final approval of the protocol and informed consent. I was informed that I can’t initiate this study until I receive approval through the USAMRAA Contracting Office. Therefore, I have no results to report at the present time.

Breast neoplasms, proteomics, serum, tumor markers biological

Unclassified

Unclassified

Unclassified

Unlimited
Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cover</td>
<td>1</td>
</tr>
<tr>
<td>SF 298</td>
<td>2</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>3</td>
</tr>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>4</td>
</tr>
<tr>
<td>Conclusions</td>
<td>4</td>
</tr>
<tr>
<td>References</td>
<td>4</td>
</tr>
<tr>
<td>Appendices</td>
<td></td>
</tr>
</tbody>
</table>
Introduction

The purpose of our proposed work is to study differences in serum protein expression profiles between healthy women and women with breast cancer, and to discover novel tumor markers. We intend to generate proteomics spectra on serum samples from 100 healthy women and 100 breast cancer patients. The goal of this analysis is to identify serum proteomic patterns using a matrix-assisted laser desorption ionisation that can distinguish women with breast cancer from healthy women. The origin and full identity of the discriminating proteins or peptides will be investigated.

Body

The protocol is under review by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I received their first review of the protocol and informed consent on January 21, 2004, and replied to their comments and concerns on January 30, 2004. I received a second review with additional comments on June 1, 2004 and I replied on June 10, 2004.

Key Research Accomplishments

N/A

Reportable Outcomes

N/A

Conclusions

We are awaiting the final approval of the protocol and informed consent by the Office of Regulatory Compliance and Quality at U.S. Army Medical Research and Materiel Command. I was informed that I can’t initiate this study until I receive approval through the USAMRAA Contracting Office. Therefore, I have no results to report at the present time.

References

N/A